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Metabolic syndrome, which can include weight gain and central obesity, elevated serum insulin and glucose, and insulin resistance,
has been strongly associated with breast cancer recurrence and worse outcomes after treatment. Epidemiologic and prospective
data do not show conclusive evidence as to which dietary factors may be responsible for these results. Current strategies employ
low-fat diets which emphasize supplementing calories with increased intake of fruit, grain, and vegetable carbohydrate sources.
Although results thus far have been inconclusive, recent randomized trials employing markedly diﬀerent dietary strategies in
noncancer patients may hold the key to reducing multiple risk factors in metabolic syndrome simultaneously which may prove to
increase the long-term outcome of breast cancer patients and decrease recurrences. Since weight gain after breast cancer treatment
confers a poor prognosis and may increase recurrence rates, large-scale randomized trials are needed to evaluate appropriate
dietary interventions for our breast cancer patients.
1. Introduction
Recent data has elucidated the connection between obesity,
metabolic syndrome, and poor outcomes in breast can-
cer patients. Metabolic syndrome, also known as insulin
insensitivity syndrome, is defined as central obesity in
addition to two of the following risk factors: elevated glucose,
insulin resistance, elevated triglycerides, reduced high-
density lipoproteins (HDLs), and hypertension [1]. Breast
cancer patients with metabolic syndrome undergoing
chemotherapy were found to have an overall poor response
to treatment and those patients who specifically had high
blood glucose levels were noted to have increased rates of
disease progression [2]. Additionally, obesity-related vari-
ables in early stage breast cancer are significantly associated
with recurrence [3]. Data from prospective studies have
demonstrated an association between obesity and cancer-
specific mortality in multiple sites [4], and weight gain in
breast cancer patients is associated with worse outcomes [5].
Prospective data from Italy in patients undergoing surgery
and chemotherapy for breast cancer has shown an increase
in tumor recurrence in patients with high fasting blood glu-
cose level, low high-density lipoprotein levels, hypertrigly-
ceridemia, large waist circumference, and hypertension [6].
Although dietary strategies are not often imparted
to patients completing treatment in the survivorship
stage of disease, recently, more eﬀort has been made to
invoke dietary modification. Most dietary strategies have
focused on reducing fat and increasing fruits, vegeta-
bles, and grains in an attempt to decrease recurrence
risk.
This paper serves to review the basic pathways in which
obesity and metabolic syndrome may function to increase
the risk of recurrence in patients treated for breast cancer
and will discuss the current controversy in potential dietary
strategies to treat both metabolic and cancer-related issues.
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2. Obesity, Weight Gain, and
Breast Cancer Outcome
At diagnosis, women with breast cancer who are overweight,
obese, or have android body fat distribution experience
increased risk of local recurrence, cancer-related death, and
overall death by up to 540% [7, 8]. Data have revealed that
patients weighing over 130 pounds at cancer diagnosis have
inferior recurrence-free survival [9]. Other data point to
worse pathological response to chemotherapy in overweight
and obese patients [10].
However, the eﬀect on outcomes is not only limited to
excess weight at presentation, as weight gain after diagnosis
of breast cancer negatively impacts disease-free survival, local
recurrence, and death as well. In a large cohort of patients
followed for nearly 7 years, women who gained more than
5.9 kg after diagnosis were 1.5 times more likely to experience
disease recurrence and 1.6 times more likely to die of their
disease [11]. In the Nurses’ Health Study, which prospectively
followed over 5,000 women for several decades, weight and
weight gain were associated with increased rates of breast
cancer recurrence and mortality [12].
Unfortunately, while weight gain after diagnosis portends
a poorer prognosis, the majority of women appear to gain
weight after breast cancer diagnosis, with studies showing
weight gain occurring in 50–96% of patients [13]. Changes
in patient metabolism, physical activity, and dietary intake
are proposed mechanisms for this weight gain; however, as
discussed below, dietary recommendations may be partly to
blame. In fact, most commonly, patients gain over 5.9 kg,
which is a risk factor for tumor recurrence [13, 14]. Other
studies show that premenopausal women gain significantly
more weight than postmenopausal women, and up to 20%
gain over 10 kg within 60 weeks of treatment [11]. While
weight gain in general is associated with several risk factors
for breast cancer recurrence, more specifically, worse out-
comes are likely linked to disturbed adipose tissue meta-
bolism resulting from (a) failure to accommodate surplus
nutrients in adipose tissue that leads to ectopic accumulation
of fat in other tissues and (b) qualitative and/or quantitative
changes in physiologic processes, including adipokine pro-
duction.
2.1. Adipokine Secretion by Adipose Tissue. Adipose tissue,
especially centrally located adipose tissue, creates several
physiological conditions favoring inflammation within the
body (Figure 1). Dysregulation of cellular growth, angiogen-
esis stimulation, and extracellular matrix remodeling favor-
ing tumor progression and recurrence has been shown to
result from adipokine secretion from adipose tissue [15]. Fat
cells secrete the inflammatory mediators tumor necrosis
factor alpha (TNFα), interleukin 6 (IL-6), and retinol-
binding protein-4 (RBP4). TNFα has been shown to promote
breast cancer growth through the activation of several
intracellular molecular pathways, including MAPK, kappa
B (NF-kappa B), and the PI3-K/Akt pathway [16]. Current
clinical studies are testing therapeutic TNFα inhibitors for
metastatic breast cancer, illustrating this relationship [17].
Inflammation is well known to negatively aﬀect the
tumor environment, increasing cellular proliferation, tumor
survival, and metastasis [18]. Inflammation has also been
shown to modify the body’s immune response to cancer cells
and the response of tumor cells to chemotherapy. Inflam-
mation and proinflammatory cytokines can activate stromal
cells in the surrounding extracellular matrix, including fibro-
blasts, vascular endothelial cells, and macrophages [19]. A
growing body of laboratory research has shown that proin-
flammatory cytokines synthesized by adipose tissue can facil-
itate tumor growth andmetastasis by altering tumor cell biol-
ogy and activating stromal cells in the tumor microenviro-
nment, such as vascular endothelial cells, tumor-associated
macrophages, and fibroblasts.
Several inflammatory markers have been correlated
with worse prognosis in breast cancer patients. Studies
in metastatic breast cancer have shown that IL-6 was
independently correlated with shorter survival [20, 21]. IL-6
was also found to be predictive of nodal involvement, tumor
size at initial diagnosis, progression, and experiencing mul-
tiple metastatic sites [22, 23]. Other work has shown C-
reactive protein (CRP) to be predictive for survival in newly
diagnosed metastatic breast cancer patients [24]. The Glas-
gow Prognostic Score, which is based on CRP and systemic
inflammatory response, significantly predicts for survival in
metastatic breast cancer patients [25].
In a cohort of over 700 women, circulating levels of CRP
and serum amyloid A were associated with reduced disease-
free and overall survival. High levels of these inflammatory
markers were also associated with a doubling of the risk of
recurrence and mortality in a cohort of women diagnosed
with breast cancer [26].
Disruption in transcription of IL-6 through gene poly-
morphisms results in modified serum levels of the cytokine
via regulation of gene transcription and has been shown to
be associated with disease-free survival [27, 28].
Leptin, another cytokine produced and secreted by
adipose tissue, is necessary for normal breast gland develop-
ment. It is present in normal serum, but can be increased
nearly 20-fold in obese individuals [29]. Both in vitro and
animal studies have shown that increased levels from excess
adipose tissue may activate several molecular and signaling
pathways that induce the proliferation of normal and cancer
cells, resulting in tumor survival and progression [30]. Leptin
has also been shown to stimulate angiogenesis and activate
insulin-like growth factor 1 (IFG-1), resulting in increased
tumor invasion and metastasis [31].
Conversely, adiponectin, which is also secreted by adi-
pose tissue, is decreased in obese individuals and those that
are insulin resistant. It appears to function in opposition
of leptin, blocking its tumorigenic eﬀects, and an increased
ratio of leptin to adiponectin leads to tumor proliferation
in breast cancer cells [32]. A case-control study found that
serum adiponectin is inversely related to breast cancer risk
[33].
Overall, strong evidence exists for inflammation leading
to poorer outcomes in breast cancer patients and increased
rates of recurrence. Excess adipose tissue, most notably in a
centralized location, appears to modulate this inflammation,
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Figure 1: The eﬀect of adipose tissue and serum glucose on several metabolic risk factors for breast cancer recurrence. Legend: the figure
above illustrates the interplay between weight gain and several metabolic factors associated with breast cancer recurrence. ∗represents a
factor that is known to influence recurrence. IGF-1: insulin-like growth factor 1 receptor, SHBG: sex hormone-binding globulin, TNFα:
tumor necrosis factor alpha, IL-6: interleukin 6, RBP4: retinol-binding protein-4, CRP: C-reactive protein, 17β-HD: 17β-hydroxysteroid
dehydrogenase.
leaving central fat reduction as a potential method on
reducing breast cancer recurrence.
2.2. The Eﬀects of Adipose Tissue on Estrogen and Sex
Hormones. More than 80% of breast cancers in women older
than 45 years of age express receptors including estrogen and
other sex hormone receptors [34]. Accordingly, high lev-
els of circulating estrogens have been correlated with an
increased risk of breast cancer recurrence after treatment
[35]. Increased recurrence is likely a factor of estrogen’s eﬀect
on cell proliferation through direct stimulation of breast
tumor cells and mitogenic activity, as well as through the
initiation of increased production of hormones and growth
factors that stimulate tumor growth and progression [36].
Adipose tissue is capable of peripheral conversion of
androgen precursors formed in the adrenal glands and
ovaries to estrogen via the enzymes aromatase and 17β-
hydroxysteroid dehydrogenase [36], serving as an extrago-
nadal source of estrogen production [37]. Obese patients,
and notably obese postmenopausal women, have increased
levels of the circulating estrogens, estrone, and estradiol and
decreased levels of sex hormone-binding globulin (SHBG)
[38], which binds and inhibits estradiol. This combination
leaves obese patients with elevated active serum estrogens
that are potentially capable of fueling tumor progression and
recurrence (Figure 1). Lower levels of SHBG also result in
increased levels of circulating unbound androgens which
may result in tumor progression by themselves and further
conversion to estrogens by adipose tissue and associated
tumor eﬀects [39]. Furthermore, estrogens upregulate leptin
expression, leading to progression of breast cancer cells.
Excess adipose tissue has also been shown to result in
increased circulating insulin and IFG-1 [40, 41] which results
in poorer outcomes and is discussed below.
2.3. Insulin, Insulin Resistance, Blood Glucose, and Breast
Cancer Outcome. Biologically, obesity is associated with high
levels of circulating insulin, decreased insulin sensitivity, and
insulin resistance [42]. Elevated insulin levels with corre-
sponding insulin resistance and elevated blood glucose have
been correlated with poor outcomes in breast cancer patients
[43–46]. Reasons for poor prognosis have yet to be elucidated
andmay prove to bemultifactorial. Tumor data have revealed
that cancer cells exhibit increased glucose consumption [47],
and elevated blood glucose may result in the fueling of cancer
cells. TheWomen’s Healthy Eating and Living (WHEL) study
assessed hemoglobin A1C (HbA1C) in 3,003 survivors with
early stage breast cancer and found that elevated serum
glucose decreased disease-free survival and significantly
reduced overall survival [43]. Though it was not powered to
detect a diﬀerence in recurrence, the results remain mean-
ingful, revealing a 30% reduction in recurrence rate. Unfor-
tunately, glucose intolerance frequently occurs during adju-
vant treatment of breast cancer with chemotherapy [48].
As the principle source of energy of cancer cells, elevated
serum glucose in itself may fuel tumor progression [49].
Moreover, chronically elevated levels of serum glucose
predispose patients to insulin resistance and elevated serum
insulin [41], whichmay exert their own eﬀects on tumor pro-
gression. RBP4, the inflammatory mediator mentioned
previously, induces insulin resistance, further connecting
obesity, inflammation, and insulin resistance. Both insulin
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and IFG-1 have been shown to increase cell proliferation,
protect cells from apoptosis, and induce cellular pathways
known to result in worse cancer-related outcomes [46, 50].
As breast tumors often express higher levels of the IGF-1
receptor [51–54], it is of no surprise that insulin and IFG-
1 have been correlated with early recurrence and decreased
relapse-free survival in breast cancer as well as increased
resistance of tumor cells to both chemotherapy and radiation
therapy [45, 46]. Elevated levels of insulin also result in the
inhibition of SHBG [55] synthesis and therefore an increase
in circulating steroids, as described previously.
In a cohort of over 500 women without known diabetes
followed prospectively, fasting insulin levels correlated with
distant recurrence and death after breast cancer treatment
[44]. Women in the highest quartile of insulin had a twofold
increase in the risk of tumor recurrence and a threefold
increase in risk of death versus those patients in the lowest
quartile. Obese patients also have higher levels of circulating
free IGF-1 and serum insulin [40], and a reduction of obesity
remains a potential target of decreasing insulin, IGF-1, and
insulin resistance. However, it is unclear if such eﬀorts would
reduce the risk of recurrence from circulating serum glucose
levels and whether this would need to be accomplished
through dietary changes.
Recent literature has revealed that diabetic patients on
metformin have a lower incidence of invasive breast cancer
[56], and those with breast cancer experience higher rates of
complete response to chemotherapy [57]. Metformin, which
works by sensitizing patients to insulin to lower circulat-
ing glucose and insulin levels, further connects metabolic
syndrome with treatment outcomes in breast cancer. The
eﬀect of insulin on recurrence and survival is being addressed
in the recent NCIC Clinical Trials Group MA.32, which is
a phase III randomized trial of metformin versus placebo
in early stage breast cancer patients. However, it remains
unknown if the usage of metformin may benefit patients by
mitigating all mechanisms of metabolic syndrome, or if it
merely improves insulin resistance.
3. Current Controversies in Metabolic and
Weight Management during Breast Cancer
3.1. Fear of Weight Loss during Cancer Treatment. Weight loss
during cancer treatment was associated with worse outcomes
in several cancer sites, as it was a powerful predictor of
outcome in lung cancer [58] and was found to be the biolog-
ical result of increased energy expenditure and malnutrition
[59]. Thus attempts weremade to limit malnutrition through
liberalizing dietary constraints to maximize caloric intake
by all potential means, often including high-carbohydrate
sources. However, attempts at nutritional intervention to
avoid weight loss have thus far provided limited patient ben-
efit [60], as it appears that weight loss and cachexia may be
less a function of patient malnutrition and more likely a
component of several factors, including the result of aggres-
sive tumor biology and metabolism [61]. In cancers that
impair food absorption and the ability to eat, and those with
treatment toxicity that limits oral intake, such as esophageal
and head and neck cancer, this strategy may be eﬃcacious.
However, treatment-related malnutrition is rare in breast
cancer patients, with the majority of patients gaining weight
during treatment [14], making such a strategy imprudent in
breast cancer.
Accordingly, weight loss may be the result of the aggres-
sive biology and associated decreased survival rather than the
cause of the poorer outcomes. Aggressive attempts at weight
maintenance and even weight gain during treatment may not
serve to help the patient’s prognosis, but rather to supply
a metabolically active tumor with an increased source of
nutrients and fuel. However, an analysis from our institution
reveals that online recommendations for cancer patients
during treatment and after, including breast cancer patients,
often recommend a calorie-dense diet with the purpose of
weight maintenance or even weight gain (manuscript cur-
rently under review). As a result, women may be following
recommendations for patients with cancer of other disease
sites, putting them at increased risk of weight gain.
Moreover, it appears that a majority of women are inter-
ested in dietary changes during cancer treatment [62, 63].
Data from our institution reveals that a majority are even
interested in engaging in significant dietary changes within
the setting of a clinical trial during cancer treatment and after
(manuscript currently under review).
3.2. Methods of Dietary Intervention. The abundance of data
demonstrating a correlation between both weight gain and
metabolic syndrome and inferior treatment outcomes in
breast cancer patients has prompted increased evaluation of
dietary methods to address these factors. However, contro-
versy exists in defining the appropriate dietary measures to
achieve these results.
Epidemiologic and prospective data have evaluated the
relationship between dietary intake, breast cancer recurrence,
and overall survival. However, results have thus far been
inconsistent [8], likely due to varied study methods. These
studies rely on patient self-reporting and food diaries,
which are both techniques fraught with error, bias, and
inaccuracy [64–67], with the strongest bias towards patient
recall of high-fat foods [8]. Epidemiologic data have shown
a potential link between dietary fat and breast cancer risk,
which has led dietary fat to come under the most scrutiny
by prospective studies. Results have been inconsistent with
several showing worse outcomes with fat intake. Also, when
energy intake is adjusted for, the eﬀect of fat on outcome is
no longer significant in many of these studies [8].
Epidemiological findings that fruit and vegetable con-
sumption may increase survival after diagnosis of breast
cancer [68] have also led to several intervention trials that
promote the reduction of fat and its replacement with
carbohydrate sources. Interestingly, data show that after
breast cancer diagnosis, patients actually appear to make
lifestyle changes akin to these recommendations, including
increasing fruit and fiber intake and decreasing fat intake
[62]. So far, results of these trials have produced no definitive
conclusions, with the WHEL study yielding negative results
and the Women’s Intervention Nutrition Study (WINS)
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showing that a low-fat diet may decrease breast cancer recur-
rence [69, 70]. However, weight loss in the WINS study may
have been the predominate factor resulting in a reduction
in breast cancer recurrence rather than a low-fat diet itself,
as patients in the WHEL study, which was negative, gained
weight on a low-fat diet [71, 72].
While these trials provide some evidence of guidelines
that could be implemented in our patients, from a biological
standpoint it seems that there is some cause for concern as
this disease derives energy primarily from glucose. Accord-
ingly, several risk factors associated with elevated serum glu-
cose, including elevated insulin and insulin resistance, have
been associated with increased recurrence and worse out-
comes, as discussed previously. This eﬀect is compounded
by the increase in glucose utilization by tumor cells, as
tumors derive a majority of their energy from the process
of anaerobic metabolism of glucose [49]. Along these lines,
tumors need excess amounts of glucose to fuel this ineﬃcient
process, and as per data previously, if elevated serum
levels are present, these patients may be at increased risk
of tumor recurrence. Therefore, replacing dietary fat with
carbohydrate sources in cancer patients may be reducing a
major source of energy for normal cells and replacing it with
fuel for tumor cells.
3.3. What Is the Optimal Dietary Strategy? A dietary strategy
with primary emphasis on decreasing obesity, excess weight,
and central adipose tissue would hold the most promise
in reducing disease recurrence and improving outcomes, as
these factors appear to be strongly correlated with worse
outcomes (Figure 2). Decreasing adiposity may result in
reduced systemic inflammation, circulating hormones, and
insulin. Data from the recent prospective trials described
previously, would also favor methods of decreasing serum
glucose and insulin levels while increasing insulin sensitivity
through diet, all of which are associated with a favorable
prognosis. Such factors may actually suggest limiting sugar,
carbohydrates, and foods that increase serum insulin and
glucose levels. As a result, an optimal diet approach may
actually include limiting carbohydrates, and counter to
traditional recommendations, replacing these dietary sources
with fat and protein.
3.4. Do Recommendations Reflect the Data? Currently, physi-
cians typically recommend a low-fat diet with a high con-
sumption of fruits and vegetables, based on epidemiologic
and observational data. While a low-carbohydrate, and by
default, higher-fat diet is in contradiction to this con-
ventional advice, recent high-level evidence in noncancer
patients has shown this diet to produce successful weight
reduction in the majority of randomized studies when com-
pared head-to head with a low-fat diet [73]. While several
studies have revealed a low-fat and low-carbohydrate diet to
be comparable in terms of weight loss, a meta-analysis of
13 randomized trials from 2002 to 2007 revealed superior
weight loss with a low-carbohydrate diet versus a low-fat diet
at 6months, though at one year the diﬀerence was only found
to be 1.05 kg [74]. However, at one year, favorable changes
were seen in changes in several risk factors for breast cancer
recurrence, including HDL, triglycerides, and systolic blood
pressure in the low-carbohydrate groups. Recent trials show
more favorable weight reduction with low-carbohydrate
dietary strategies [73]. However, while the low-fat diets in
these studies were similar to the intervention arms in the
WINS and WHEL study, diets in recent randomized trials
were followed under close supervision, removing erroneous
food questionnaire techniques by providing more accurate
methods, including weighed food records and weekly coun-
seling [75, 76]. Yet, not only have these studies illustrated
successful weight reduction through a low-carbohydrate diet,
but all metabolic factors associated with breast recurrence,
including inflammation, central adipose tissue, serum glu-
cose and insulin levels, and insulin resistance were shown to
be positively aﬀected through these diets.
In fact, a recent trial randomized noncancer patients
to a low-carbohydrate or low-fat diet with the primary
endpoint of improving several metabolic factors that are also
risks for breast cancer recurrence. The low-carbohydrate
group experienced significantly more weight loss and reduc-
tion in adipose tissue, improved blood glucose levels and
insulin sensitivity, and increases in HDL, all risk factors
for metabolic syndrome and breast cancer recurrence [75].
Also, six markers of inflammation, including TNF and IL-
6, underwent a greater decrease in the low-carbohydrate
group compared to the low-fat group. These results were
confirmed in another randomized trial revealing that a
low-carbohydrate diet increased insulin sensitivity by 55%,
decreased serum insulin by 50%, while decreasing serum
glucose, adiposity, triglycerides, and increasingHDL. Inflam-
matory markers in this study were evaluated as well,
illustrating an improvement in all 16 biomarkers in the
low-carbohydrate arm, including RBP4, while the low-fat
diet showed no benefit in any of the inflammatory markers
[76]. A similar study found that a comparable low-carb diet
significantly lowered CRP in patients with high metabolic
risk factors [77].
However, the likely increase in saturated fat that would
ensue on a low-carbohydrate diet provides some caution
for physicians. Along these lines, the same group compared
serum amounts of saturated fat in each diet group [75]. They
found that even though the low-carbohydrate group ate three
times the amount on saturated fat as the low-fat group, less
circulating saturated fat was found in the serum of these
patients. It is increased circulating saturated fatty acids, not
dietary saturated fat intake, that is associated with increased
risk of developing metabolic syndrome [78], diabetes [79],
heart attack [80], heart failure [81], and perhaps breast can-
cer [82]. Of note, the low-fat group consumed a mean 267 g
carbohydrates per day while the low-carbohydrate group
ate a mean of 45 g. This was likely an eﬀect of decreased levels
of serum insulin, as insulin stimulation is known to increase
fat storage in adipose tissue, while low insulin levels result in
fat oxidation [41].
Several other randomized trials have confirmed the
superiority of a low-carbohydrate diet in regard to weight
loss, decreased serum glucose and insulin levels, increased
insulin sensitivity, and decreased blood pressure [83–88].
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Figure 2: Optimal dietary strategy to reduce breast cancer recurrence risk. Legend: an optimal dietary strategy in reducing breast cancer
recurrence would incorporate methods to decrease weight loss, while simultaneously decreasing the risk factors of metabolic syndrome.
HDL: high-density lipoprotein, TG: triglycerides.
However, several studies found that when calories were held
constant, low-carbohydrate diets were also superior to low-
fat diets in regards to weight loss [76, 87, 88], which may
point to a metabolic eﬀect connecting insulin, blood glucose,
insulin sensitivity, and lipogenesis, all factors that, if reduced,
may favorably eﬀect breast cancer prognosis.
In conclusion, traditional dietary recommendations of
limiting fat while favoring dietary carbohydrates may be a
suboptimal strategy for improving nearly every metabolic
risk factor for breast cancer recurrence, including decreasing
adipose tissue, serum glucose, serum insulin, and inflamma-
tory factors, while increasing HDL and insulin sensitivity.
4. Conclusions
Metabolic syndrome, including weight gain, elevated glu-
cose, and insulin resistance, has been strongly associated
with breast cancer recurrence and worse outcomes after
treatment. While patients appear to limit fat consumption
and increase vegetable and fruit consumption once cancer is
diagnosed [62], the majority of patients still gain weight after
breast cancer diagnosis. Thus far, dietary intervention trials
have been limited, and methods of decreasing metabolic syn-
drome and obesity in noncancer patients have shown results
counter to current dietary strategies in breast cancer patients.
Large-scale randomized trials evaluating appropriate dietary
interventions to reduce breast cancer recurrence, includ-
ing a low-carbohydrate approach, are desperately needed.
Incorporation of evidence from current randomized trials in
noncancer patients may be eﬃcacious.
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